SynAct Pharma
15,35
SEK
-4,06 %
Mindre end 1K følgere
SYNACT
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Finansielt overblik og estimater
Ownership
-4,06%
-1,03%
+71,22%
+41,85%
+83,96%
+112,48%
-84,47%
+94,52%
+233%
SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2016 and is headquartered in Lund, Sweden.
Læs mereMarkedsværdi
752,29 mio. SEK
Aktieomsætning
2,68 mio. SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
27.5
2025
Delårsrapport Q1'25
27.5
2025
Generalforsamling '25
20.8
2025
Delårsrapport Q2'25
ViserAlle indholdstyper
Pivotal US Patent Protecting Resomelagon (AP1189) Granted to SynAct Pharma
SynAct’s Nomination Committee proposes Jeppe Ragnar Andersen to the Board
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools